Key result
Cerivastatin lowers LDL-C by ~41%, outperforming lower-dose cerivastatin and pravastatin.
Why the study?
Statins are the agents of choice for reducing elevated plasma LDL-C, and this study tested whether cerivastatin 0.8 mg has greater long-term efficacy than pravastatin 40 mg in primary hypercholesterolemia.
RCT (n=1,170)
Double-blind
Parallel-group, 4:1:1 ratio
Answers are grounded in this paper and cite their sources.
Cerivastatin 0.8 mg yields greater LDL-C reduction than pravastatin 40 mg; confirms superior long-term efficacy in primary hypercholesterolemia.
BACKGROUND: Statins are the agents of choice in reducing elevated plasma low-density lipoprotein cholesterol (LDL-C). HYPOTHESIS: Cerivastatin 0.8 mg has greater long-term efficacy in reducing LDL-C than pravastatin 40 mg in primary hypercholesterolemia. METHODS: In this double-blind, parallel-group, 52-week study, patients (n = 1,170) were randomized (4:1:1) to cerivastatin 0.8 mg, cerivastatin 0.4 mg, or placebo daily. After 8 weeks, placebo was switched to pravastatin 40 mg. Patients with insufficient LDL-C lowering after 24 weeks were allowed open-labeled resin therapy. RESULTS: Cerivastatin 0.8 mg reduced LDL-C versus cerivastatin 0.4 mg (40.8 vs. 33.6%, p <0.0001) or pravastatin 40 mg (31.5%, p<0.0001), and brought 81.8% of all patients, and 54.1% of patients with atherosclerotic disease, to National Cholesterol Education Program (NCEP) goals. Cerivastatin 0.8 mg improved mean total C (-29.0%), triglycerides (-18.3%), and high-density lipoprotein cholesterol (HDL-C) (+9.7%) (all p < or = 0.013 vs. pravastatin 40 mg). Higher baseline triglycerides were associated with greater reductions in triglycerides and elevations in HDL-C with cerivastatin. Cerivastatin was well tolerated; the most commonly reported adverse events were arthralgia, headache, pharyngitis, and rhinitis. Symptomatic creatine kinase > 10x the upper limit of normal (ULN) occurred in 1, 1.5, and 0% of patients receiving cerivastatin 0.8 mg, cerivastatin 0.4 mg, and pravastatin 40 mg, respectively. Repeat hepatic transaminases >3 x ULN occurred in 0.3-0.5, 0.5, and 0% of patients, respectively. CONCLUSION: In long-term use, cerivastatin 0.8 mg effectively and safely brings the majority of patients to NCEP goal.
No takes yet. Share an insight, caveat, or question.
Isaacsohn et al. (2001) conducted an RCT in Primary hypercholesterolemia (n=1,170). Cerivastatin vs. Cerivastatin 0.4 mg daily, or placebo daily switched to pravastatin 40 mg daily after 8 weeks was evaluated on Reduction in low-density lipoprotein cholesterol (LDL-C) (p=<0.0001). Cerivastatin reduced LDL-C by 40.8% compared with 33.6% for cerivastatin and 31.5% for pravastatin.
Synapse has enriched 10 related papers. Consider them for comparative context: